جست‌وجوی استاد و پژوهشگر

Stephan Reuterمشاهده پروفایل

استاد

• Plasma Physics
• Plasma Medicine
• Ultrafast Laser Spectroscopy
• +۴ مورد دیگر

Stephan Reuter is a Full Professor in the Department of Engineering Physics at Polytechnique Montréal , holding the TransMedTech Research Chair in Plasma Medicine . His work bridges plasma physics, biomedicine, and environmental technology through advanced diagnostics and interdisciplinary applications. Education: Dipl. Phys.-Ing. (Master in Engineering Physics), Dipl. Phys. (M.Sc. in Physics), Dr. rer. nat. (PhD) Affiliations: TransMedTech Institute, Institute of Biomedical Engineering, Alexander von Humboldt Foundation Alumnus Research Interests: Non-thermal plasma physics, plasma medicine, ultrafast laser diagnostics, plasma-liquid interactions, environmental remediation His 15 most recent publications (2022-2025) focus on cold atmospheric plasma jets for cancer therapy, agricultural sustainability, and microfluidic integration. These works span Plasma Medicine , Environmental Technology , and Advanced Diagnostics , with specific subfields like 3D tumor modeling, reactive oxygen species analysis, and precision plasma dosimetry. Scientific Leadership : Feodor Lynen Research Fellow (Princeton University, 2017-2018) Co-founder of Leibniz Institute's Plasma Medicine Group Editorial contributor to Plasma Sources Science and Technology Research Impact : Over 98 peer-reviewed journal articles Keynote speaker at ISPC26 (2025) Major grants: $3.4M for greenhouse plasma technology (2024), $1M NFRF Exploration Grant (2021) Labs & Collaborations : Polytechnique Montréal Plasma Biophysics Lab TransMedTech Institute International collaborations: Leibniz Institute (Germany), Queens University (UK), Lublin University (Poland)

• Public Health
• Cardiovascular Health
• Data Linkage
• +۳ مورد دیگر

Iain Atherton is a researcher at Edinburgh Napier University’s School of Health and Social Care , with a focus on public health , cardiovascular health , and data linkage . His work spans epidemiological studies, healthcare policy analysis, and nursing education reform, often utilizing large-scale datasets to explore social determinants of health outcomes. Key research areas include public health , healthcare services , and population health Current projects investigate nurse workforce dynamics , Covid-19’s impact on chronic disease management , and deprivation-related health disparities His recent publications analyze hypertension telemonitoring , nursing smoking behaviors , and end-of-life care patterns . Collaborations include institutions like the British Heart Foundation and Scottish Government . While not explicitly stated, his active involvement in funded projects (e.g., N50k Programme , Scale up BP ) suggests ongoing faculty status.

• Plastic Surgery
• Reconstructive Surgery
• Breast Reconstruction
• +۶ مورد دیگر

Afshin Mosahebi serves as an Honorary Professor in the Department of Surgical Biotechnology at University College London (UCL), where he maintains an active research profile despite his non-salaried academic appointment. His work bridges surgical innovation with biotechnology applications, focusing on evidence-based improvements in plastic and reconstructive surgical outcomes while addressing contemporary challenges in healthcare sustainability and patient safety. Primary Affiliation: Department of Surgical Biotechnology, UCL Academic Status: Honorary (non-salaried) faculty position Research Scope: Clinical and translational surgical research with global health implications Professor Mosahebi's research program demonstrates exceptional breadth across surgical disciplines, with concentrated expertise in DIEP flap breast reconstruction techniques, melanoma management, and sustainable surgical practices. His methodology frequently employs systematic reviews, bibliometric analyses, and eco-audits to evaluate surgical efficacy and environmental impact. Key specialties include peripheral nerve imaging advancements, aesthetic medicine evidence assessment, and psychological outcomes in cosmetic surgery patients. The work consistently addresses unmet needs in surgical oncology, reconstructive microsurgery, and resource optimization within healthcare systems. Analysis of his 330+ publications reveals three dominant research trajectories: (1) Technical refinement in breast reconstruction (particularly venous augmentation to prevent fat necrosis), (2) Sustainability quantification across surgical pathways (breast, abdominal, microtia), and (3) Critical appraisal of evidence in aesthetic medicine (botulinum toxin, regenerative therapies, patient psychology). His collaborative approach spans oncology, dermatology, psychology, and environmental science, evidenced by multi-disciplinary co-authorship patterns. The temporal concentration of 2025 publications indicates ongoing high productivity in surgical innovation research. While no specific awards are documented in available records, Professor Mosahebi's extensive publication record—including leadership in high-impact systematic reviews and novel eco-audit methodologies—demonstrates significant scholarly contribution. His supervisory role is evidenced by thesis editorial involvement (e.g., FRAME project) and frequent student co-authorship, though formal student lists remain unspecified. Collaborative networks prominently feature researchers like Wong ZY and Faderani R across multiple projects, indicating sustained research partnerships. Current work shows particular emphasis on environmental impact assessment and evidence-based protocol development for surgical safety.

Martha L. Bulykمشاهده پروفایل

استاد

• Transcription factors
• DNA regulatory elements
• Genomics
• +۵ مورد دیگر

Martha L. Bulyk is a Professor of Medicine and Pathology at Harvard Medical School, with appointments in the Division of Genetics at Brigham & Women's Hospital. She serves as Co-Chair of the Harvard Biophysics Graduate Program and holds associate memberships at the Broad Institute of MIT and Harvard and the Dana-Farber Cancer Institute Center for Cancer Systems Biology. Her laboratory is located in the New Research Building at Harvard Medical School in Boston. Her research focuses on decoding transcriptional regulation through the study of transcription factors (TFs) and DNA regulatory elements. Using integrated experimental and computational genomics approaches, her lab investigates: High-throughput analysis of TF-DNA binding specificities Cis-regulatory codes in eukaryotic genomes Effects of protein interactions and DNA structure on TF function Molecular determinants of protein-DNA binding specificity and evolution Impact of genetic variation on human transcription factors Pioneer factor interactions with nucleosomes Regulatory functions of alternative TF isoforms in breast cancer Quantitative information encoding in transcriptional enhancers/silencers Recent publications demonstrate a strong focus on mechanistic studies of transcriptional regulation, with recurring themes in chromatin dynamics, cancer biology (particularly neuroblastoma and breast cancer), developmental gene regulation, and computational method development. Her work frequently integrates structural, evolutionary, and functional genomics approaches. The Bulyk Laboratory currently comprises 2 graduate students, 3 postdoctoral fellows, 4 technicians, and 2 undergraduate students. The lab participates in multiple Harvard University programs including the Biophysics PhD Program, Biological & Biomedical Sciences (BBS) PhD Program, Systems/Synthetic/Quantitative Biology PhD Program, Bioinformatics & Integrative Genomics (BIG) PhD Program, and the School of Public Health Program in Quantitative Genomics.

Ben Maozمشاهده پروفایل

استاد

• Biomedical Engineering
• Nanotechnology
• Neuroscience
• +۴ مورد دیگر

Prof. Ben Maoz is a Professor at the Department of Bio-Medical Engineering , The Iby and Aladar Fleischman Faculty of Engineering , Tel Aviv University . He directs the MaozLab, which pioneers interdisciplinary research in neuroengineering, microphysiological systems, and nanoscale therapeutic delivery. His lab integrates engineering principles with neuroscience to model human diseases and develop translational technologies. Research Focus Prof. Maoz's research spans: Organ-on-Chip Platforms : Developing modular microfluidic systems (e.g., neurovascular units, PNS-CNS models) for disease modeling and drug screening. Nanoneuroengineering : Designing brain-targeted nanocarriers (liposomes, dendriplexes) for siRNA and antibody delivery in neurodegenerative disorders like Parkinson's. Medical Devices : Creating implantable sensors, nanogenerators for sensory restoration, and tools for traumatic brain injury analysis. Cellular Mechanobiology : Investigating biomechanical forces in tissues using magnetoresponsive hydrogels and 3D cultures. Publication Trends His recent work (2023-2025) emphasizes: Advanced drug delivery systems for neurological applications (e.g., siRNA to neurons, alpha-synuclein-targeting antibodies). Innovative organ-on-chip platforms for studying cancer metastasis, viral entry, and neuro-immune interactions. Biomaterials and nanotechnologies addressing sensory restoration, cellular contractility, and super-resolution imaging. Laboratory & Collaborations The MaozLab employs microfabrication, molecular biology, and in vitro modeling to tackle challenges in brain health, with collaborations spanning oncology, virology, and gastroenterology.

• Cancer Biomarkers
• Tumor-Agnostic Research
• Precision Medicine
• +۶ مورد دیگر

Karin Jirström is a Professor at the Department of Therapeutic Pathology, Faculty of Medicine, Lund University. She leads the LUCC: Lund University Cancer Centre and serves as Vice Dean at the Faculty of Medicine. Her research focuses on tumor-agnostic cancer biomarker discovery and adaptive treatment strategies. Roles: Professor, Head of Division, Vice Dean, Principal Investigator, Supervisor Key Institutions: Lund University, Faculty of Medicine, Therapeutic Pathology, LUCC Research Interests: Jirström specializes in tumor-agnostic biomarkers, exploring tumor heterogeneity and clonal evolution to improve treatment for pancreatic, liver, biliary tract, and colorectal cancers. Her lab maintains extensive tissue microarray resources and conducts prospective clinical trials to optimize precision oncology. Recent Article Trends: Her 2024-2025 publications emphasize biomarker validation across multiple cancers, integrating epigenetics, machine learning, and tumor microenvironment dynamics. Key themes include adaptive therapy in colorectal cancer, chemoresistance in breast cancer, and liquid biopsy applications in PDAC. Supervision: She mentors students in projects like BILLIONSTARS (bile duct/liver cancer) and On-CALL (metastatic colorectal cancer), focusing on translational research and clinical collaborations. Labs & Collaborations: Jirström co-manages the Immunohistochemistry and Tissue Microarray Center Malmö, fostering interdisciplinary work with clinicians and researchers in cancer evolution and adaptive therapies.

Linda Lindströmمشاهده پروفایل

دانشیار

• Breast Cancer
• Cancer Epidemiology
• Endocrine Treatment
• +۴ مورد دیگر

Linda Lindström is an Associate Professor and Senior Researcher at the Department of Oncology-Pathology, Karolinska Institutet. She leads a research group focused on translational breast cancer studies, particularly long-term risk factors and endocrine treatment benefits for estrogen receptor-positive (ER+) breast cancer patients. Her work addresses the heterogeneity of tumor progression and the clinical implications of intra-tumor variability in receptor expression. Education: MSc in Molecular Biotechnology, Uppsala University (1997-2001); PhD in Cancer Epidemiology, Karolinska Institutet (2004-2008). Employment: Postdoctoral positions at Karolinska Institutet (2008-2012) and UCSF (2012-2014); Senior Researcher (2022-present). Her research integrates molecular and clinical expertise to identify biomarkers for metastasis risk prediction, with a focus on ER+ tumors, gene signatures, and tumor microenvironment interactions. She investigates how intra-tumor heterogeneity affects treatment outcomes and survival, particularly in premenopausal vs. postmenopausal patients. Recent publications highlight interdisciplinary collaborations analyzing tamoxifen’s long-term efficacy, genomic risk stratification, and immune microenvironment influences. Awards include the Swedish Cancer Society Senior Investigator Award (2022-2028), supporting her team’s work on individualized treatment strategies.

• Conversation Analysis
• Healthcare Communication
• Clinical Communication
• +۵ مورد دیگر

Dr. Sarah White is an Adjunct Senior Lecturer in the Discipline of General Practice within the Faculty of Medicine & Health at the University of New South Wales. With a Doctor of Philosophy from the University of Otago (2011) and a Bachelor of Arts (Hons) in Linguistics and Spanish and Latin American Studies from UNSW (2006), she brings a strong interdisciplinary background to her work in healthcare communication. As a conversation analyst, Dr. White specializes in researching real-world clinical interactions, with particular focus on surgeon-patient consultations, telehealth communication, and pain talk. Her work bridges linguistic theory and practical healthcare applications, developing data-driven training approaches to improve clinical communication. She has published extensively in healthcare communication journals and serves on the editorial boards of BJGP Open, Qualitative Health Communication, and Health Literacy and Communication Open. Dr. White's recent publications (2023-2025) reveal a consistent research trajectory examining communication dynamics across various healthcare contexts, with increasing attention to telehealth implementation challenges and opportunities. Her work employs rigorous conversation analysis methodology to extract practical insights for clinical practice, showing particular interest in how communication patterns affect patient outcomes and clinical decision-making. Her notable achievements include receiving the 2021 Australian Award for University Teaching Citation, being awarded Senior Fellow of Advance HE (SFHEA) in 2019, and securing significant research funding including a $95,000 Avant Foundation grant for telehealth research (2021-2023). She is also the founder and director of Bedside Manners Pty Ltd, providing healthcare communication training services. As an educator, Dr. White supervises research students including Avisak Bhattacharjee (University of Adelaide) and Kanesha Ward (Macquarie University), and has contributed to curriculum development in medical education. Her research has been supported by multiple grants from UNSW Health@Business Network, Avant Foundation, and Macquarie University, totaling over $140,000 in the past decade. Dr. White maintains active professional engagement through the International Society for Conversation Analysis (ISCA) and the International Association for Communication in Healthcare (EACH), contributing to the global advancement of healthcare communication research and practice.

Emma Warneckeمشاهده پروفایل

مدرس پزشکی

• Medical Education
• Stress Management
• Mindfulness
• +۳ مورد دیگر

Dr Emma Warnecke is a Medical Educator affiliated with the School of Medicine at the University of Tasmania , Australia. Her research focuses on stress management, mindfulness interventions, and mental health in medical and doctoral education. Current position: Medical Educator, School of Medicine, University of Tasmania Key affiliations: Menzies Research Institute, School of Medicine Contact: emma.warnecke@utas.edu.au Her research explores the impact of mindfulness training on stress reduction in medical and doctoral students, with longitudinal studies on psychological well-being and performance. She has also investigated barriers to lifestyle risk factor management, medical student selection tools, and rural clinical training. Her publications demonstrate a sustained focus on integrating mindfulness into medical education, workplace mental health, and chronic disease management. Collaborative work with Menzies Research Institute highlights her interdisciplinary approach.

ORHAN ZENGİNمشاهده پروفایل

دانشیار

• Rheumatology
• Internal Medicine
• Behçet's Disease
• +۷ مورد دیگر

Orhan Zengin is an Associate Professor at Gaziantep University Faculty of Medicine, Department of Internal Medicine, specializing in Rheumatology. He has held this position since 2021, following previous roles as a Research Assistant at the same institution from 2007-2012 and 2014-2017. His academic journey began with a Medical License from Firat University Faculty of Medicine (2001-2007), followed by Medical Specialization in Internal Medicine at Gaziantep University (2007-2012), and further subspecialty training in Rheumatology (2014-2017). Dr. Zengin has also served in external roles as a Specialist Doctor at the Ministry of Health Ersin Arslan State Hospital (2019-2021) and completed mandatory service at the Ministry of Health (2017-2019). He is an active member of the Turkish Rheumatology Association since 2014 and holds an EULAR Ultrasonography certificate (intermediate level). His research focuses on Rheumatology with particular emphasis on Behçet's disease, Spondyloarthritis, Rheumatoid arthritis, Autoimmune diseases, Vasculitis, and Fibromyalgia. A distinctive aspect of his work involves analyzing the quality of medical information on YouTube, with multiple publications examining this digital health education resource for conditions like psoriatic arthritis, osteoporosis, gout, and biologic therapy side effects. Dr. Zengin has published 41 peer-reviewed articles in international and national journals, along with 3 book chapters on rheumatic diseases. His research demonstrates strong clinical relevance with significant contributions to understanding disease patterns in Turkish populations. He has supervised 4 specialist theses on various rheumatology topics and presented his work at numerous national and international conferences, with 69 documented presentations. As an educator, he teaches doctoral courses on rheumatologic symptoms, extremity examination, and specific rheumatic conditions. His work bridges clinical practice, academic research, and digital health education, making significant contributions to rheumatology both nationally and internationally.

Holly Wilkinsonمشاهده پروفایل

مدرس

• Wound Healing
• Cellular Senescence
• Diabetic Wound Repair
• +۴ مورد دیگر

Dr Holly Wilkinson is a Lecturer in Wound Healing at the Hull York Medical School, University of Hull, where she conducts research within the Centre for Atherothrombosis and Metabolic Disease. Her work focuses on understanding the cellular and molecular mechanisms underlying impaired wound healing in elderly and diabetic patients. Dr Wilkinson earned her BSc (Hons) in Zoology and MRes in Biological Sciences at the University of Manchester before completing an MRC iCASE PhD in wound healing at the University of Hull, where she received no corrections. She previously worked as a KTP associate developing wound models to test antimicrobial products. Her primary research interests center on three major areas: determining the mechanistic drivers of senescence in poor wound healing, understanding the role of endogenous metals in diabetes, ageing and skin repair, and developing novel methods to tackle wound biofilm infection. She employs a range of methodologies including in vitro, ex vivo and in vivo wound models, RNA-Seq, ptychographic imaging, and metagenomics. Analysis of her recent publications reveals a strong focus on cellular senescence, particularly in diabetic wounds, and the role of the skin microbiome in chronic wound pathology. Her work increasingly explores therapeutic interventions targeting senescent cells and microbial communities to accelerate tissue repair. Dr Wilkinson has received multiple prizes for her outstanding achievements in wound healing research and has published numerous high-impact papers in the field of skin and wound biology. She actively supervises multiple PhD and MSc students and collaborates with organizations including Diabetes UK, the British Skin Foundation, and the National Biofilms Innovation Centre. Her current projects focus on understanding why senescent cells cause poor wound healing and developing treatments to eliminate these cells, as well as creating selective antimicrobial therapies for skin infections. Dr Wilkinson leads research within the Wound Innovation Centre and works closely with industry partners to translate academic findings into clinical applications that benefit patients.

Xiaojing Maمشاهده پروفایل

استاد

• Tumor Immunology
• Cancer Immunotherapy
• UBR5 E3 Ubiquitin Ligase
• +۴ مورد دیگر

Professor Xiaojing Ma is a tenured faculty member at Weill Cornell Medicine's Graduate School of Medical Sciences, serving in the Department of Microbiology and Immunology. His research focuses on tumor immunology and cancer immunotherapy, particularly studying UBR5 E3 ubiquitin ligase in breast and ovarian cancers. Education: Bachelor of Science in Animal Science, Beijing Agricultural University, China (1982) PhD in Molecular Genetics, University of Edinburgh, UK (1987) Research Interests: Professor Ma's laboratory conducts cutting-edge research in tumor immunology using animal models of breast and ovarian cancers. His work centers on understanding the mechanisms of immunosuppression in cancer and developing novel targets for cancer immunotherapy. A major focus is the UBR5 pathway, a HECT domain E3 ubiquitin ligase that acts as a cross-cancer regulator of tumorigenesis and anti-tumor immunity. His team explores UBR5's immunological role in identifying neoantigens for cancer vaccine development and investigates molecular degraders of UBR5 via PROTAC technology for therapeutic applications. Current Research Projects: Identification of UBR5's E3 ligase substrates and interacting protein partners Discovery of tumor-associated antigens in UBR5-deficient tumors for cancer vaccine development Investigation of UBR5's immunoregulatory activities on myeloid cells in the tumor microenvironment Exploration of UBR5's role in T cell lineage development and tumor immunity Development of molecular degraders targeting UBR5 via PROTAC technology Research Trends: Professor Ma's research spans cancer immunotherapy, tumor immunology, and molecular oncology, with particular emphasis on ubiquitin-mediated protein degradation pathways. His work bridges basic science discoveries in molecular immunology with translational applications in cancer treatment, focusing on developing novel immunotherapeutic strategies against aggressive and therapy-resistant malignancies. Professional Affiliations: Department of Microbiology and Immunology, Weill Cornell Medicine Immunology & Microbial Pathogenesis Program Laboratory Focus: The Ma laboratory employs state-of-the-art technologies and experimental strategies to explore the pathophysiology and immunobiology of UBR5, an enigmatic molecule with significant clinical potential. The lab's research aims to bring immediate clinical benefits to patients with highly aggressive and therapy-resistant cancers through immune activation and generation of T cell memories for long-term immunosurveillance against cancer recurrence.

Semra Günayمشاهده پروفایل

استاد

• Breast Health
• Breast Diseases
• Breast Surgery
• +۴ مورد دیگر

Prof. Dr. Semra Günay is a distinguished Professor of General Surgery at Istanbul Okan University Hospital, specializing in Breast Surgery and Endocrine Surgery. She has extensive experience in breast cancer treatment, intraoperative radiotherapy, and oncoplastic surgery techniques. Her clinical work focuses on providing comprehensive care for patients with breast diseases and endocrine disorders. Her educational background includes: Medical degree from Istanbul University Faculty of Medicine Specialized training in Breast Cancer Surgery, Intraoperative Radiotherapy (IORT), and Oncoplastic Surgery at Marian and Luisen Breast Center in Düsseldorf, Germany Prof. Günay's research interests center around breast health and cancer treatment innovations. She has conducted significant work on intraoperative radiotherapy techniques for breast cancer patients, comparing outcomes between different radiation approaches. Her research particularly examines cosmetic results and local recurrence rates following breast-conserving surgery. She also investigates age-related differences in breast cancer presentation and treatment outcomes, with special focus on elderly patients. Her work extends to multidisciplinary approaches in breast cancer diagnosis and management. Her publication record demonstrates a strong focus on breast cancer treatment innovations, particularly in the areas of intraoperative radiotherapy and oncoplastic techniques. She has contributed to national consensus guidelines for breast cancer management during the COVID-19 pandemic, showing her leadership in adapting cancer care to emergency situations. Her work spans clinical research, surgical technique refinement, and multidisciplinary approaches to breast cancer care, with significant contributions to understanding treatment outcomes across different age groups. Prof. Günay has been actively involved in numerous national and international conferences as a speaker and moderator, particularly in the fields of breast surgery and endocrine surgery. She has contributed to book chapters on thyroid and parathyroid diseases and has participated in developing national guidelines for breast cancer management. Her expertise is frequently sought for challenging cases in thyroid and adrenal surgery. She has served in various professional capacities including as a moderator for oncological surgery courses and as a presenter at numerous national surgical congresses. Her work extends to multidisciplinary breast cancer committees where she contributes to comprehensive patient care approaches, emphasizing the importance of collaborative decision-making in complex cancer cases.

Carolyn L Smithمشاهده پروفایل

استاد

• Molecular Pharmacology
• Estrogen Receptor Function
• Transcriptional Coactivator/Repressor Interactions
• +۳ مورد دیگر

Carolyn L Smith, Ph.D., serves as Dean at the Graduate School of Biomedical Sciences and holds the Professor title in the Department of Molecular & Cellular Biology and Department of Urology at Baylor College of Medicine . She has been instrumental in graduate education since the 1990s, including roles as Assistant Dean for Curriculum and Senior Associate Dean for Graduate Education & Academic Program Development. Education : Ph.D. in Biochemistry (University of Western Ontario, 1992), B.S. in Biochemistry (University of Toronto, 1986) Her research focuses on molecular pharmacology of estrogen receptors , regulation of gene expression by coactivators/corepressors , and steroid hormone action in breast/urothelial carcinomas , with particular interest in tamoxifen resistance mechanisms . She has directed the Tissue and Cell Culture Core facility since 1994, mentoring 6 Ph.D. students and 24 postdoctoral fellows. Scientific Recognition : Nichols Institute New Investigator Award North American Menopause Society SERM Research Award University of Western Ontario Collip Silver Medal for Medical Sciences Molecular & Cellular Biology Department Award of Excellence in Education & Service As an academic administrator, she has driven curriculum innovation, program assessment, and professional development initiatives for graduate students and postdoctoral trainees. Her laboratory contributions include 3D cell culture model development and translational research on hormone-dependent cancers.

Shiqin Liuمشاهده پروفایل

استادیار مدعو

• Cancer Biology
• Molecular Oncology
• Biomarker Development
• +۷ مورد دیگر

Shiqin Liu is an Assistant Adjunct Professor at the University of California, Los Angeles (UCLA) in the Department of Molecular and Medical Pharmacology. As a clinician-scientist with translational focus, their work bridges clinical practice and cancer research through biomarker development and therapeutic innovation. MD, Central South University (2012) PhD in Oncology, Peking University (2017) Joint PhD, University of Miami (2016) Residency in Surgery, Central South University (2019) Postdoctoral Fellow, Stanford University (2019-2023) Postdoctoral Fellow, UCLA (2023) Their research focuses on identifying molecular drivers of cancer progression and developing clinical-grade diagnostic tools and therapies. Key areas include: Proteomics-based biomarker discovery for high-risk cancers Antibody-targeted therapies and imaging agents Mechanistic studies of neuroendocrine prostate cancer 3D tumor modeling and optical diagnostics Recent publications highlight their work on: Trop2 as a prognostic urinary biomarker for prostate cancer UCHL1's dual role in tumor growth and therapeutic targeting Novel drug targets like CDC7 and CXCR4/CB2 heterodimers Biofabrication techniques for cancer modeling Laboratory affiliations include: Stoyanova Lab at UCLA (2023-present) Stoyanova Lab at Stanford University (2019-2023)